New Delhi, May 17 (PTI) Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales.

The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.

Also Read | JEE Advanced 2024 Admit Card Out at jeeadv.ac.in: Hall Ticket for Joint Entrance Examination Advanced Exam Released, Know Steps To Download.

Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement.

For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal.

Also Read | Sikkim Day 2024 Date: Know the History and Significance of Sikkim Foundation Day That Marks the Formation of the 22nd State of India.

"Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said.

The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders.

Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)